About Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) is a rare neurodegenerative tauopathy characterized by 4-repeat tau (4R-tau) accumulation in neurons and glia of the brainstem, basal ganglia, and cerebral cortex. The Richardson syndrome (PSP-RS) phenotype is most common, featuring vertical supranuclear gaze palsy, early postural instability with falls, dysarthria, and cognitive decline. PSP is uniformly fatal, with a median survival of 5-7 years from symptom onset.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Progressive Supranuclear Palsy trials.
Movement Disorder Society PSP diagnostic criteria (probable or possible) must be met — vertical gaze palsy documentation is required
CSF neurofilament light chain (NfL) and CSF total tau are biomarkers used in trial stratification
Anti-tau therapies (ASOs, antibodies) are the primary investigational approaches — disease duration of <4 years is a common eligibility cut-off
Functional status (PSP Rating Scale score) and mobility documentation are required baseline measures
Patient Resources
Find recruiting Progressive Supranuclear Palsy trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Progressive Supranuclear Palsy. Updated daily.